NCT05188170View on ClinicalTrials.gov

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 21, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

Niclosamide

Niclosamide will be administered orally for 14 days. Each dose will be followed by backbone chemotherapy

Trial Locations (1)

94305

RECRUITING

Stanford University, Palo Alto

All Listed Sponsors
collaborator

The Leukemia and Lymphoma Society

OTHER

collaborator

Pediatric Cancer Research Foundation (PCRF)

UNKNOWN

collaborator

CURE Childhood Cancer, Inc.

OTHER

lead

Stanford University

OTHER